For research use only. Not for therapeutic Use.
Cardionogen 1 (CDNG1/vuc230) is a Wnt signaling pathway inhibitor that slows down Myc-induced liver tumorigenesis. Cardionogen 1 treatment of zebrafish embryos before gastrulation inhibits cardiomyocyte formation, whereas treatment during or after gastrulation induces cardiomyocyte formation. Cardionogen 1 has potential in research into cancer and cardiovascular disease[1][2].
| Catalog Number | R042178 |
| CAS Number | 577696-37-8 |
| Synonyms | 6-cyclohexyl-3-(furan-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole |
| Molecular Formula | C13H14N4OS |
| Purity | ≥95% |
| InChI | InChI=1S/C13H14N4OS/c1-2-5-9(6-3-1)12-16-17-11(10-7-4-8-18-10)14-15-13(17)19-12/h4,7-9H,1-3,5-6H2 |
| InChIKey | SWTUPSNBTSPBIH-UHFFFAOYSA-N |
| SMILES | C1CCC(CC1)C2=NN3C(=NN=C3S2)C4=CC=CO4 |
| Reference | [1]. Yan C, et al. Chemical inhibition reveals differential requirements of signaling pathways in krasV12- and Myc-induced liver tumors in transgenic zebrafish. Sci Rep. 2017 Apr 5;7:45796. [2]. Plowright AT, et al. Heart regeneration: opportunities and challenges for drug discovery with novel chemical and therapeutic methods or agents. Angew Chem Int Ed Engl. 2014 Apr 14;53(16):4056-75. |
